Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
KTTA Pasithea Therapeutics
0.697-0.002-0.29%
Close
01/27 16:00 ET
0.685-0.012-1.71%
Post Mkt Price 01/27 19:51 ET
High
0.700
Open
0.676
Turnover
59.55K
Low
0.676
Pre Close
0.699
Volume
87.42K
Post-Market
5D
1D
1W
1M
1Q
1Y
Price Forecast
News
Comment
Pasithea Announces Contract With WuXi STA to Produce PAS-004
Pasithea Therapeutics Signs CMC Development And Manufacturing Agreement For The Production Of PAS-004
Pasithea Therapeutics Corp. (NASDAQ:KTTA) ("Pasithea" or the "Company"), a biotechnology company focused on the discovery, research and development of innovative treatments for Central Nervous System
Generex Biotechnology (OTCMKTS:GNBT) Vs. Pasithea Therapeutics (NASDAQ:KTTA) Head-To-Head Analysis
Generex Biotechnology (OTCMKTS:GNBT – Get Rating) and Pasithea Therapeutics (NASDAQ:KTTA – Get Rating) are both small-cap medical companies, but which is the superior business? We will compare the tw
12 Health Care Stocks Moving In Wednesday's After-Market Session
GainersQuotient (NASDAQ:QTNT) stock rose 35.8% to $0.33 during Wednesday's after-market session. This security traded at a volume of 1.0 million shares come close, making up 143.5% of its average volu
12 Health Care Stocks Moving In Thursday's After-Market Session
GainersCue Health (NASDAQ:HLTH) shares rose 13.3% to $2.73 during Thursday's after-market session. The company's market cap stands at $407.9 million. Pasithea Therapeutics (NASDAQ:KTTA) shares increas
Stocks That Hit 52-Week Lows On Wednesday
 On Wednesday, 152 stocks made new 52-week lows. Areas of Interest About Today's 52-Week Lows: Tesla (NASDAQ:TSLA) was the largest firm on a market cap basis to set a new 52-week low.Pingtan Marine
Pasithea Therapeutics Corp. (NASDAQ:KTTA) Short Interest Update
Pasithea Therapeutics Corp. (NASDAQ:KTTA – Get Rating) saw a significant increase in short interest during the month of November. As of November 30th, there was short interest totalling 209,800 share
Press Release: Majority of Stockholders Support Pasithea Directors at Special Meeting
Majority of Stockholders Support Pasithea Directors at Special Meeting MIAMI BEACH, Fla., Dec. 14, 2022 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (Nasdaq: KTTA) ("Pasithea" or the "Company"), a
Pasithea Therapeutics Says It Has Agreed to Buy All Shares of Its Common Stock Held by Camac at $1.0003/Shr >KTTA
Pasithea Therapeutics: Camac Agrees to 3-Yr Standstill Provision; Parties Agree to Dismiss the Pending Litigation >KTTA
Company Overview
More
Pasithea Therapeutics Corp. is a biotechnology company focuses on the research and discovery of new and treatments for psychiatric and neurological disorders. The company was founded by Yassine Bendiabdallah and Steinman Lawrence J in May, 2020 and is headquartered in Miami Beach, FL.
CEO： Dr. Tiago Reis Marques
Market： NASDAQ
Listing Date： 09/15/2021
Paper Trade
More
Hot List
TradeSearchNews
SymbolLatest price%Chg
Loading...
Watchlist
No Stock Yet